Furthermore, it is possible that therapeutic treatment could be helpful for the MES status of NB (PRRX1, NFATC2, RAC2, VAV1), which showed a higher degree of inflammatory characterization and possible immunological vulnerability. The gene discussed is PRRX1; the disease is neuroblastoma.